Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ravulizumab versus placebo study in adults with amyotrophic lateral sclerosis
NL-OMON55160Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ravulizumab in amyotrophic lateral sclerosis (ALS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline in ALSFRS-R total score at Week 50. Started Aug 2020; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON55160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55160.